- In May 2024, Thermo Fisher Scientific expanded its cell culture media manufacturing capabilities in Singapore, opening a new biologics facility aimed at meeting growing regional demand for GMP-compliant, chemically defined media. This strategic move enhances supply chain resilience and accelerates delivery to key Asia-Pacific markets, reinforcing Thermo Fisher’s commitment to localizing high-quality bioprocessing solutions
- In April 2024, HiMedia Laboratories, a major Indian biosciences firm, launched a new range of serum-free and xeno-free media formulations tailored for stem cell and vaccine research. This development addresses the rising need for standardized, regulatory-compliant media across India's growing biopharma and academic sectors, positioning HiMedia as a key player in Asia-Pacific’s media innovation landscape
- In March 2024, Cytiva announced a collaboration with China’s Wuxi Biologics to co-develop optimized cell culture media formulations specifically designed for monoclonal antibody production. The partnership leverages Cytiva’s global expertise and Wuxi’s manufacturing infrastructure to support scalable biologics development, illustrating the region’s growing emphasis on localized, customized bioprocess solutions
- In February 2024, JXTG Nippon Oil & Energy Corporation (Japan) entered the biotechnology market by investing in cell culture media production facilities, targeting demand for regenerative medicine and diagnostic applications in East Asia. This diversification signals increased cross-sector participation in Asia-Pacific’s biomanufacturing ecosystem
- In January 2024, Kangstem Biotech (South Korea) introduced a proprietary stem cell culture medium under its StemCure line, designed for enhanced proliferation and differentiation of mesenchymal stem cells. This innovation supports South Korea’s push into advanced cell therapy development, further reinforcing regional leadership in regenerative medicine applications
